Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 10/28/20
End: 10/25/21
Due: 10/25/22
Phase: N/A
Priority: Normal
Start: 08/23/24
End: 12/31/28
Due: 12/31/29
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Phase 1 SAD and MAD Study of the Safety, Tolerability and PK of 7HP349 in Normal Healthy Male Subjects | NCT04508179 | 7 Hills Pharma, LLC | user2@example.com | None | 2020-10-28 | 2021-10-25 | 2022-10-25 | - | - | 2025-07-14 |
| A Study of Oral 7HP349 (Alintegimod) in Combination with Ipilimumab Followed by Nivolumab Monotherapy | NCT06362369 | 7 Hills Pharma, LLC | user2@example.com | None | 2024-08-23 | 2028-12-31 | 2029-12-31 | - | - | 2025-07-14 |